Abstract
Although the US Preventive Services Task Force and other contemporary guidelines recommend that Menopausal Hormone Therapy (MHT) not be used for prevention of chronic conditions, its use for prevention of cardiovascular disease remains controversial. The Women's Health Initiative and the Heart and Estrogen/progestin Replacement Study explored the benefits and risks of MHT for cardiovascular disease, primary and secondary prevention respectively, but challenges to these data include suboptimal hormone therapy adherence and the advanced age of the women at initiation of MHT. Here we discuss the recent literature impacting MHT management of the peri- and post-menopausal women who are concerned about cardiovascular disease risk.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Current Treatment Options in Cardiovascular Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
